



Proteomics International

LABORATORIES LTD

ASX Release
17 December 2025

ASX code: PIQ

US patent secured for PromarkerEso diagnostic test for esophageal adenocarcinoma

- Patent granted in USA protecting the intellectual property for PromarkerEso proprietary blood test for the early diagnosis of esophageal adenocarcinoma (EAC)
- Major milestone as the patent underpins the commercialisation pathway in the world's largest healthcare market, enabling direct sales, future partnerships and licensing opportunities
- Patents for the PromarkerEso diagnostic test now cover multiple jurisdictions including Australia, China, Hong Kong, Europe and the USA
- Global health impact: currently 90% of EAC cases go undetected until late stage, leading to a median survival time of less than one year - EAC is commonly caused by chronic acid reflux or GERD, which is present in 20% of people in the USA

Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ), a pioneer in precision diagnostics, is pleased to announce it has secured new intellectual property protection with the US Patent Office granting a patent for PromarkerEso, the proprietary first-in-class blood test for esophageal adenocarcinoma (EAC).

Esophageal cancer represents a critical global health challenge, ranking seventh in cancer-related mortality and eleventh in overall prevalence. Esophageal adenocarcinoma, the predominant form of esophageal cancer, is commonly caused by chronic acid reflux, also known as gastroesophageal reflux disease (GERD), and is often asymptomatic in its early stages. It is estimated that approximately 20% of people in the United States have GERD¹.

The five-year survival rate for EAC is less than 20% with median survival time less than one year². The current gold-standard screening for the disease requires a specialist endoscopy, however this invasive procedure can be uncomfortable and costly for patients (US\$2,750 in the US³) and despite this surveillance up to 90% of EAC cases continue to go undetected⁴.

Proteomics International Managing Director Dr Richard Lipscombe said, *"This is a significant achievement because the USA is the largest and most advanced healthcare market in the world. Securing patent protection for our diagnostic technology there is a key step in our commercialisation pathway and provides a strong foundation for potential partnerships, licencing, and regulatory advancement."*

PromarkerEso has demonstrated high accuracy in clinical studies for detecting EAC, including the early stages of the disease [ASX: 5 June, 18 September]. The test aims to address a major unmet need in the timely and accurate diagnosis of EAC, improving patient outcomes and reducing healthcare costs.

The granted patent, titled *'Glycoprotein Biomarkers For Esophageal Adenocarcinoma And Barrett's Esophagus And Uses Thereof'* (US Patent No. 17165803), provides intellectual property protection in the

¹ www.yalemedicine.org/conditions/gerd-gastroesophageal-reflux-disease

² Nature Reviews Gastroenterology & Hepatology, 2021, doi.org/10.1038/s41575-021-00419-3

³ www.newchoicehealth.com/endoscopy/cost

⁴ Diseases of the Esophagus, 2025, doi: 10.1093/dote/doi038

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

USA until 28 February 2036 for the Company's novel diagnostic test. Patent protection for PromarkerEso test covers multiple jurisdictions, including Australia, China, Hong Kong, Europe and the USA.

There is a growing incidence of EAC, potentially related to western diet, hence there is an urgent need for a more efficient, accurate, and patient-friendly diagnostic pathway.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX: PIQ).

ENDS

About Promarker®Eso

PromarkerEso is a first-in-class blood test that utilises biomarkers—'fingerprints' in the blood—to measure the risk of having esophageal adenocarcinoma (EAC). The test combines four key serum glycoproteins (alpha-1-antitrypsin, alpha-1-antichymotrypsin, complement C9, and plasma kallikrein) with patient clinical factors age, sex, and body mass index (BMI). These are analysed through a proprietary algorithm to generate a clear and simple 'traffic light' risk score for EAC, classifying individuals as low-, moderate-, or high-risk for the disease. Patients identified as high risk of having EAC are recommended to consult a gastroenterologist. PromarkerEso has patents granted in Europe, China and Australia, with other territories pending.

Proteomics International recommends that patients concerned about chronic acid reflux or GERD seek advice from their doctors.

Further information on managing chronic reflux is available through the www.mytest.health web portal.

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of precision diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Matthew Wright
Media and Public Relations
NWR Communications
T: +61 451 896 420
E: matt@nwrcommunications.com.au

Dirk van Dissel
Investor Relations & Corporate Advisory
Candour Advisory
T: +61 408 326 367
E: dirk@candouradvisory.com.au